Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Non-Current Liabilities (2019 - 2021)

Keros Therapeutics' Other Non-Current Liabilities history spans 3 years, with the latest figure at $16000.0 for Q3 2021.

  • For Q3 2021, Other Non-Current Liabilities fell 79.22% year-over-year to $16000.0; the TTM value through Sep 2021 reached $16000.0, down 79.22%, while the annual FY2020 figure was $62000.0, 47.9% down from the prior year.
  • Other Non-Current Liabilities reached $16000.0 in Q3 2021 per KROS's latest filing, down from $32000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $119000.0 in Q4 2019 to a low of $16000.0 in Q3 2021.
  • Average Other Non-Current Liabilities over 3 years is $68500.0, with a median of $69500.0 recorded in 2020.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 47.9% in 2020, then tumbled 79.22% in 2021.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $119000.0 in 2019, then tumbled by 47.9% to $62000.0 in 2020, then tumbled by 74.19% to $16000.0 in 2021.
  • Per Business Quant, the three most recent readings for KROS's Other Non-Current Liabilities are $16000.0 (Q3 2021), $32000.0 (Q2 2021), and $47000.0 (Q1 2021).